No Data
No Data
BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.
BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.
Express News | BridgeBio Pharma, Inc. : H.c. Wainwright Cuts Target Price to $43 From $47
Promising Clinical Data Bolsters Buy Rating for BridgeBio Pharma
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and
BridgeBio Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 74.46% Evercore ISI Group → $50 Initiates Coverage On → Outperform 03/20/2024 57.01% JP Morgan
Buy Rating on BridgeBio Pharma: Enhanced Market Prospects From Acoramidis Efficacy and Mortality Benefit
No Data